Metabolic therapy of support in complex treatment of a chronic hepatitis C

The article represents the results of the different treatment schemes of patients with chronic virus hepatitis C and nonalcoholic steatohepatitis (NASH) with dyslipidemia. The benefit of additional metabolic therapy (ademetionine, fishant S, enterosanum, essliver forte, fructus silybi mariani) in combination with standard treatment by interferon alpha (produced in Russian Federation) plus ribavirin was shown. This benefit includes decreasing of the grade of liver steatosis according to sonographic assessment and improvement of lipid metabolism: 15% decreasing of triglicerid level and low-density lipoprotein cholesterol, 20-30% decreasing of apolipoprotein B, 15-30% increasing high-density lipoprotein cholesterol concentrations and 25% increasing of apolipoprotein A in plasma. The hypolipidemic effect of the metabolic therapy began not earlier then in 6 months after the start of the treatment and achieved maximum in a year. The positive dynamics of clinical features - disappearing or significant decreasing of asthenovegetative and dyspepsic syndromes, reducing of liver dimension was shown in all groups independently of metabolic therapy.

steatohepatitis, chronic hepatitis C, dyslipidemia